Oncotarget

Research Papers:

Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications

Siker Kimbung _, Anikó Kovács, Anna Danielsson, Pär-Ola Bendahl, Kristina Lövgren, Marianne Frostvik Stolt, Nicholas P Tobin, Linda Lindström, Jonas Bergh, Zakaria Einbeigi, Mårten Fernö, Thomas Hatschek and Ingrid Hedenfalk

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:33306-33318. https://doi.org/10.18632/oncotarget.5089

Metrics: PDF 1154 views  |   HTML 1463 views  |   ?  


Abstract

Siker Kimbung1,2, Anikó Kovács3, Anna Danielsson4, Pär-Ola Bendahl1, Kristina Lövgren1, Marianne Frostvik Stolt5, Nicholas P. Tobin5, Linda Lindström6,7, Jonas Bergh5, Zakaria Einbeigi4, Mårten Fernö1, Thomas Hatschek5, Ingrid Hedenfalk1,2

1Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden

2CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden

3Department of Clinical Pathology and Cytology, Sahlgrenska University Hospital, Gothenburg, Sweden

4Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5Department of Oncology and Pathology, Karolinska Institutet and Karolinska University Hospital, Sweden

6Department of Surgery, University of California at San Francisco (UCSF), San Francisco, CA, USA

7Department of Biosciences and Nutrition, Karolinska Institutet and University Hospital, Solna, Sweden

Correspondence to:

Ingrid Hedenfalk, e-mail: Ingrid.Hedenfalk@med.lu.se

Keywords: metastatic breast cancer, estrogen receptor, molecular subtype, biomarker conversion, post recurrence mortality

Received: June 12, 2015     Accepted: August 28, 2015     Published: September 08, 2015

ABSTRACT

The relevance of the intrinsic subtypes for clinical management of metastatic breast cancer is not comprehensively established. We aimed to evaluate the prevalence and prognostic significance of drifts in tumor molecular subtypes during breast cancer progression. A well-annotated cohort of 304 women with advanced breast cancer was studied. Tissue microarrays of primary tumors and synchronous lymph node metastases were constructed. Conventional biomarkers were centrally assessed and molecular subtypes were assigned following the 2013 St Gallen guidelines. Fine-needle aspirates of asynchronous metastases were transcriptionally profiled and subtyped using PAM50. Discordant expression of individual biomarkers and molecular subtypes was observed during tumor progression. Primary luminal-like tumors were relatively unstable, frequently adopting a more aggressive subtype in the metastases. Notably, loss of ER expression and a luminal to non-luminal subtype conversion was associated with an inferior post-recurrence survival. In addition, ER and molecular subtype assessed at all tumor progression stages were independent prognostic factors for post-recurrence breast cancer mortality in multivariable analyses. Our results demonstrate that drifts in tumor molecular subtypes may occur during tumor progression, conferring adverse consequences on outcome following breast cancer relapse.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5089